Basic Study
Copyright ©The Author(s) 2015.
World J Pharmacol. Jun 9, 2015; 4(2): 227-235
Published online Jun 9, 2015. doi: 10.5497/wjp.v4.i2.227
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Serum alanine transaminase, aspartate aminotransferase, alkaline phosphatase, albumin and total protein levels. I: Control group; II: Model group; III: ALHXW group; IV: High-dose of FQG groups; V: Medium-dose of FQG; VI: Low-dosage of FQG group. ALT: Alanine transaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; ALB: Albumin; TP: Total protein; FQG: Fu-qi granule.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Effect of fu-qi granule on histopathological changes of liver (hematoxylin and eosin × 10). A: Control group; B: Model group; C: ALHXW group; D: High-dose of FQG-treated rats; E: Medium-dosage of FQG-treated rats; F: Low-dose of FQG-treated rats. Black arrow represents the pathological section. FQG: Fu-qi Granule.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Immunohistochemical analysis of α-smooth muscle actin in liver from rats with liver fibrosis (× 10). A: Control group; B: Model group; C: ALHXW group; D: High-dosage of FQG-treated rats; E: Medium-dosage of FQG-treated rats; F: Low-dosage of FQG-treated rats. Black arrow represents the pathological section. FQG: Fu-qi granule.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Western blot analysis of mammalian target of rapamycin and hypoxia-inducible factor-1α expression. A: Control group; B: Model group; C: ALHXW group; D: High-dosage of FQG-treated rats; E: Medium-dosage of FQG-treated rats; F: Low-dosage of FQG-treated rats. mTOR: Mammalian target of rapamycin; HIF-1α: Hypoxia-inducible factor-1 α; FQG: Fu-qi granule.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Effect of Fu-qi granule on expression of tissue inhibitor of matrix metalloproteinases-1 and matrix metalloproteinases-9 in carbon tetrachloride induced fibrotic liver of rats. A: Normal control; B: Model control; C: ALHXW group; D: High-dosage of FQG-treated rats; E: Medium-dosage of FQG-treated rats; F: Low-dosage of FQG-treated rats; M: Marker; TIMP-1: 455 bp; MMP-9: 679 bp; TIMP-1: Tissue inhibitor of matrix metalloproteinases-1; MMP-9: Matrix metalloproteinases-9; FQG: Fu-qi granule.
Figure 6
Open in New Tab Full Size Figure Download Figure
Figure 6 Mammalian target of rapamycin/P70S6 kinase signaling pathway activation maybe participate in the process of liver fibrosis. FQG is the major negative-regulation target of mTOR. FQG paradoxically down-regulates the expression of mTOR and HIF-1α by Western blot. Then subsequently inhibit the activation of mTOR/p70S6K pathway. mTOR: Mammalian target of rapamycin; p70S6K: P70S6 kinase; FQG: Fu-qi granule; TIMP: Tissue inhibitor of matrix metalloproteinases; HIF-1α: Hypoxia-inducible factor-1 α.